Adaptive Biotechnologies Corp (ADPT)
4.37
-0.05
(-1.13%)
USD |
NASDAQ |
Nov 21, 16:00
4.57
+0.20
(+4.58%)
After-Hours: 20:00
Adaptive Biotechnologies Enterprise Value: 401.39M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 401.39M |
| November 20, 2024 | 408.77M |
| November 19, 2024 | 417.63M |
| November 18, 2024 | 447.14M |
| November 15, 2024 | 506.18M |
| November 14, 2024 | 579.97M |
| November 13, 2024 | 619.81M |
| November 12, 2024 | 631.62M |
| November 11, 2024 | 714.26M |
| November 08, 2024 | 615.38M |
| November 07, 2024 | 587.34M |
| November 06, 2024 | 605.05M |
| November 05, 2024 | 579.97M |
| November 04, 2024 | 532.74M |
| November 01, 2024 | 540.02M |
| October 31, 2024 | 470.67M |
| October 30, 2024 | 503.13M |
| October 29, 2024 | 451.49M |
| October 28, 2024 | 445.58M |
| October 25, 2024 | 413.12M |
| October 24, 2024 | 423.45M |
| October 23, 2024 | 452.96M |
| October 22, 2024 | 450.01M |
| October 21, 2024 | 427.88M |
| October 18, 2024 | 447.06M |
| Date | Value |
|---|---|
| October 17, 2024 | 441.16M |
| October 16, 2024 | 464.77M |
| October 15, 2024 | 489.85M |
| October 14, 2024 | 486.90M |
| October 11, 2024 | 485.43M |
| October 10, 2024 | 481.00M |
| October 09, 2024 | 494.28M |
| October 08, 2024 | 531.17M |
| October 07, 2024 | 554.78M |
| October 04, 2024 | 571.01M |
| October 03, 2024 | 503.13M |
| October 02, 2024 | 514.94M |
| October 01, 2024 | 497.23M |
| September 30, 2024 | 511.99M |
| September 27, 2024 | 445.31M |
| September 26, 2024 | 430.56M |
| September 25, 2024 | 297.84M |
| September 24, 2024 | 322.91M |
| September 23, 2024 | 336.18M |
| September 20, 2024 | 393.69M |
| September 19, 2024 | 412.86M |
| September 18, 2024 | 387.79M |
| September 17, 2024 | 390.74M |
| September 16, 2024 | 384.84M |
| September 13, 2024 | 387.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
35.09M
Minimum
Apr 18 2024
8.636B
Maximum
Jan 22 2021
2.349B
Average
982.73M
Median
Jul 06 2022
Enterprise Value Benchmarks
| The Cooper Companies Inc | 22.42B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.07M |
| Revenue (Quarterly) | 46.44M |
| Total Expenses (Quarterly) | 79.07M |
| EPS Diluted (Quarterly) | -0.22 |
| Gross Profit Margin (Quarterly) | 64.11% |
| Profit Margin (Quarterly) | -69.07% |
| Earnings Yield | -30.66% |
| Normalized Earnings Yield | -25.53 |